Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jan 26, 2025; 17(1): 101036
Published online Jan 26, 2025. doi: 10.4252/wjsc.v17.i1.101036
Published online Jan 26, 2025. doi: 10.4252/wjsc.v17.i1.101036
Microvesicles derived from mesenchymal stem cells: A promising therapeutic strategy for acute respiratory distress syndrome-related pulmonary fibrosis?
Zhao Zhang, Xiao-Qian Shan, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
Xin-Yun Shan, Shandong Medical College, Jinan 276000, Shandong Province, China
Ce Liang, Hebei Normal University of Science and Technology, Qinhuangdao 066004, Hebei Province, China
Lan Zhao, Tianjin Institute of Acupuncture and Moxibustion, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
Co-corresponding authors: Lan Zhao and Xiao-Qian Shan.
Author contributions: Zhang Z contributed to the writing - review & editing, original draft, visualization, validation, resources, project administration, and methodology; Zhao L and Shan XQ participated in the supervision of this manuscript; Shan XY and Liang C contributed to the paper format and layout. All corresponding authors attest to equal contributions in this article.
Supported by the National Natural Science Foundation of China, No. 82174442.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lan Zhao, MD, PhD, Professor, Tianjin Institute of Acupuncture and Moxibustion, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300381, China.
Received: September 3, 2024
Revised: November 24, 2024
Accepted: December 16, 2024
Published online: January 26, 2025
Processing time: 139 Days and 0.6 Hours
Revised: November 24, 2024
Accepted: December 16, 2024
Published online: January 26, 2025
Processing time: 139 Days and 0.6 Hours
Core Tip
Core Tip: Pulmonary fibrosis serves as a critical predictor of adverse outcomes in patients with acute respiratory distress syndrome. Currently, effective treatments for pulmonary fibrosis are notably scarce in clinical settings, highlighting the need for the identification of safe and effective therapeutic strategies. This study supports the Chen et al’s conclusion. To deepen our understanding of this novel therapeutic option, we initially review the safety and efficacy of mesenchymal stem cells therapy. Subsequently, we elaborate on the potential applications and challenges associated with mesenchymal stem cells-microvesicles as an emerging therapeutic modality.